Wells Fargo analyst Stephen Baxter raised the firm’s price target on Centene (CNC) to $44 from $43 and keeps an Equal Weight rating on the shares following Q4 results and guidance. The firm thinks that the setup for the stock from here remains difficult due to low visibility to exchanges in the first half of 2026 and likely growing concerns on Medicaid in the second half of the year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- DME Capital buys BKV, boosts PG&E in Q4
- Balanced Outlook: Raising Long-Term EPS and Target Price While Medicaid Headwinds Justify a Hold Rating
- Centene price target raised to $39 from $32 at Deutsche Bank
- CVS, ELV, CNC: Health Insurer Stocks Under Pressure as U.S. Expands Fraud Probe
- Subpoenas issued to eight health insurers by House panel, Axios reports